Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;9(1):44-52.
doi: 10.1177/1756285615601933.

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

Per Soelberg Sorensen  1 , Morten Blinkenberg  2
Affiliations
Review

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

Per Soelberg Sorensen et al. Ther Adv Neurol Disord. 2016 Jan.

Abstract

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune diseases including MS lay near at hand. Rituximab was the first therapeutic B-cell-depleting chimeric monoclonal antibody to be used successfully in MS. Ocrelizumab, a second-generation humanized anti-CD20 antibody, was explored in a large phase II, randomized, placebo-controlled multicentre trial in patients with relapsing-remitting disease. Compared with placebo, two doses of ocrelizumab (600 and 2000 mg on days 1 and 15) showed a pronounced effect on disease activity seen in magnetic resonance imaging (MRI) as gadolinium-enhanced lesions (89% and 96% relative reduction, both p < 0.001) and also had a significant effect on relapses. In exploratory analyses, both doses of ocrelizumab had better effect on gadolinium-enhanced lesions than interferon beta-1a intramuscularly that was used as a reference arm. Adverse effects were mainly infusion-related reactions, in particular during the first infusion. Serious infections occurred at similar rates in ocrelizumab and placebo-treated patients, and no opportunistic infections were reported. However, progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with anti-CD20 monoclonal antibodies for other indications. Other anti-CD20 monoclonal antibodies have been tested as treatments for MS, including ofatumumab that has shown beneficial results in placebo-controlled phase II trials in patients with relapsing-remitting MS. Ocrelizumab is now in phase III development for the treatment of relapsing-remitting MS, as well as primary progressive MS, and the results of ongoing clinical trials are eagerly awaited and will determine the place of ocrelizumab in the armamentarium of MS therapies.

Keywords: anti-CD20 monoclonal antibodies; ocrelizumab; relapsing–remitting multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anderson D., Grillo-Lopez A., Varns C., Chambers K., Hanna N. (1997) Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma. Biochem Soc Trans 25: 705–708. PM: 9191187. - PubMed
    1. Archelos J., Storch M., Hartung H. (2000) The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 47: 694–706. PM: 0010852535. - PubMed
    1. Bar-Or A., Calabresi P., Arnlod D., Markowitz C., Shafer S., Kasper L., et al. (2008) Rituximab in relapsing–remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395–400. - PubMed
    1. Bar-Or A., Fawaz L., Fan B., Darlington P., Rieger A., Ghorayeb C., et al. (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67: 452–461. PM: 20437580. - PubMed
    1. Bar-Or A., Grove R., Austin D., Tolson J., Vanmeter S., Lewis E., et al. (2014) The MIRROR study: a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and MRI efficacy of subcutaneous ofatumumab in subjects with relapsing–remitting multiple sclerosis (RRMS) (I7-1.007). Neurology 82(10 Suppl.): I7–1.

LinkOut - more resources